leadf
logo-loader
viewAntisense Therapeutics Ltd

Antisense Therapeutics raises $5.5 million as it prepares to move onto Phase IIb clinical trial

The company recently completed successful dosing of patients in the Phase II clinical trial of its antisense inhibitor ATL1102 in DMD (Duchenne muscular dystrophy).

Antisense Therapeutics Ltd - Antisense Therapeutics raises $5.5 million as it prepares to move onto Phase IIb clinical trial
The company received significant support from major shareholders and new institutional investors

Antisense Therapeutics Ltd (ASX:ANP) has received a full options exercise of $5.5 million via conversion and underwriting of listed options that expired on December 19, 2019.

The company has received significant support from major shareholders and new institutional investors and sophisticated clients of Morgans Corporate Limited who participated in the underwriting.

Antisense CEO Mark Diamond said: “With additional funding received through options conversion and following successful completion of dosing in all patients in our Phase II clinical trial in DMD, which affirmed the drug’s excellent safety profile and positive drug effects on disease progression endpoints at the low dose tested, we are well placed to advance preparations for ATL1102 to move into a potentially pivotal Phase IIb clinical trial.”

ATL1102

ATL1102 is an antisense inhibitor of CD49d, a subunit of VLA-4 (Very Late Antigen-4).

Antisense inhibition of VLA-4 expression has demonstrated activity in a number of animal models of inflammatory disease including asthma and MS (multiple sclerosis) with the MS animal data having been published in a peer-reviewed scientific journal.

ATL1102 was shown to be highly effective in reducing MS lesions in a Phase IIa clinical trial in RR-MS (relapsing-remitting multiple sclerosis) patients.

Quick facts: Antisense Therapeutics Ltd

Price: 0.115 AUD

ASX:ANP
Market: ASX
Market Cap: $56.23 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Antisense Therapeutics Ltd named herein, including the promotion by the Company of Antisense Therapeutics Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Full interview: Antisense Therapeutics further develops therapeutic for...

Antisense Therapeutics Limited (ASX:ANP) managing director Mark Diamond updates Proactive on the company’s progress in developing a therapeutic for a severe disease called Duchenne Muscular Dystrophy, or DMD. The managing director spoke about the importance of the drug ATL1102 that is being...

on 4/9/19

2 min read